Scrip Intelligence presents its latest Roundtable on Managing Biotechs

Scrip Intelligence has released its latest Roundtable discussion, Capital Efficiency: Managing Biotechs in Straitened Times.

Scrip Intelligence has released its latest Roundtable discussion, Capital Efficiency: Managing Biotechs in Straitened Times.

In London at the beginning of December, Scrip Intelligence hosted a Roundtable discussion, chaired by editor-in-chief Mike Ward, to discuss...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Dermatological

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

What Incyte Investors Expect From New CEO Bill Meury

 

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By 

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

More from Therapy Areas